Validation of 1stOncology through Scientific Publications
1stOncology has been Cited, featured as a User Case and praised in Editorial Review in peer reviewed journals and leading conferences such as AACR for its excellence as a scientific competitive intelligence source.
AACR Abstract: 1stOncology assisting platform development for predicting preclinical efficacy to de-risk clinical development.
"To support predictive preclinical evaluation of immunotherapies for bone metastatic cancers, we describe a preclinical bone metastasis technology platform for evaluating efficacy of immunotherapies."
Read the full abstract here.
Citation: T. E. Kähkönen, J. M. Halleen, G. MacRitchie, R. M. Andersson, J. Bernoulli.
Immunotherapy development landscape for bone metastasis - need of predictive preclinical efficacy evaluation for de-risking clinical development [abstract]. In: Proceedings of the 115th Annual Meeting of the American Association for Cancer Research; 2024 April 5-10; San Diego, CA. Philadelphia (PA): AACR; 2024. Abstract nr 2815 / 2
User Case: Using 1stOncology to Identify Immuno-Oncology Drugs in Conjunction with Bone Metastasis
1stOncology and OncoBone, a specialist in oncology and bone diseases, recently published a peer reviewed article "Insights into immuno-oncology drug development landscape with focus on bone metastasis" in the journal Frontiers in Immunology (Impact Factor 7.3).
The novelty of this publication is based on 1stOncology, where we were able to identify novel therapies with targets or properties relevant to bone metastasis with promising data obtained during both early-stage and clinical development.
We are very pleased to see that 1stOncology could be such a substantial resource to dramatically improve the identification of immuno-oncology drug development related to bone metastasis and so rapidly provide the necessary data for this timely and very up to date publication.
Read the full paper here.
Citation: Kähkönen TE, Halleen JM, MacRitchie G, Andersson RM and Bernoulli J (2023) Insights into immuno-oncology drug development landscape with focus on bone metastasis. Front. Immunol. 14:1121878. doi: 10.3389/fimmu.2023.1121878
Published: 05 July 2023.
1stOncology Research Cited in Int J Breast Cancer
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines
"We reviewed the phenotypic and molecular characteristics of MCF10DCIS.com and the SUM cell lines based on numerous studies performed over the years. The major signaling pathways that give rise to the phenotype of these cells may serve as a good resource of information when researchers in drug discovery and development use these cells to identify novel targets and biomarkers. Major signaling pathways and mutations affecting the coding sequence are also described providing important information when using these cells as a model in a variety of studies."
Read the full paper here.
Citation: Barnabas N, Cohen D. Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer. 2013;2013:872743. doi: 10.1155/2013/872743.
Published: 16 January 2013.
1stOncology Highlighted in Editorial Review as a Novel Tool for Analyzing Cancer Immunotherapies.
"The authors summarize and short-list 24 anti-bone metastatic therapies by utilizing the novel 1stOncology database based on osteoimmuno-oncology (OIO) concept. This OIO approach deals with the interaction patterns between cancer, bone, and immune cells. Twenty drugs were short-listed from 1498 for breast cancer and 746 for prostate cancer. The authors provide an innovative approach and robust platform to identify therapies for immune activation and prevention or attenuation of bone metastasis in breast and prostate cancer."
Frontiers in Immunology (Impact Factor 7.3)
Read the full editorial here.
Citation: Sharma G, Ponzetti M, Siddiqui JA. Editorial: Bone metastasis in the milieu of osteoimmunology. Front Immunol. 2023 Aug 7;14:1265434. doi: 10.3389/fimmu.2023.1265434
Published: 07 August 2023.
Try for Free
Our 7-day trial requires no credit card and you can pick your start date!7 Day Free Trial
Library of User Cases
Whether you are in BD/S&E, Clinical Development etc. we have have a rich library of user cases for you. Some of them are even published!Track Progress & Development
Generate your own insights reports by continuously monitoring growth of companies, drugs, funding and deals in your area of interestInsights You Can Trust!
Since 1999, we have been 100% dedicated and focused on oncology and for 25 years now, we have provided our world-wide client base with the scientific and business insights required for time-saving and accurate analysis of competing drug development and corporate strategies
A Top 10 Global Pharma Analytic Provider
"Our mission is to deliver a superior intelligence service to cancer drug stakeholders and to make 1stOncology the go- to solution for those who are serious about their investment in oncology"Insights You Can Trust
Since 1999, we have been 100% dedicated and focused on oncology and for 25 years now, we have provided our world-wide client base with the scientific and business insights required for time-saving and accurate analysis of competing drug development and corporate strategies.
